Unternehmertum Venture Capital Partners has agreed to sell its shares in AMW as part of an acquisition led by Hybio Pharmaceutical and Yunfeng Capital.
A consortium led by biopharmaceutical firm Hybio Pharmaceutical and private equity firm Yunfeng Capital has agreed to acquire AMW, a Germany-based pharmaceutical firm backed by Unternehmertum Venture Capital (UVC) Partners.
The deal includes AMW’s subsidiary Endomedica. Financial terms of the acquisition, which is subject to regulatory approval, have not been disclosed.
Exiting shareholders further include development bank KfW, Bavarian state-owned BayBG Bayerische Beteiligungsgesellschaft and Bayern Kapital, through unnamed funds, as well as Saxony-Anhalt state-owned vehicle IBG Risikokapitalfonds II.
Private equity…
